Ovid Therapeutics (OVID) Free Cash Flow (2016 - 2026)

Ovid Therapeutics has reported Free Cash Flow for 11 years, with the latest figure at -$13.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 35.2% year-over-year to -$13.9 million; the trailing twelve-month figure through Mar 2026 stood at -$41.9 million (up 15.52% YoY), and the FY2025 full-year result was -$38.3 million, up 31.66% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$13.9 million, down from -$10.4 million in the prior quarter.
• The five-year high for Free Cash Flow was -$4.8 million in Q2 2025, with the low at -$20.1 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$12.4 million across 5 years, with a median of -$11.9 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 112.5% — and 2025, when it surged 66.59%.
• Ovid Therapeutics' Free Cash Flow stood at -$10.1 million in 2022, then dropped by 17.49% to -$11.9 million in 2023, then grew by 16.29% to -$10.0 million in 2024, then decreased by 3.93% to -$10.4 million in 2025, then tumbled by 33.98% to -$13.9 million in 2026.
• The last three Free Cash Flow figures came in at -$13.9 million (Q1 2026), -$10.4 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.